Rare CBD hemp strain found
BPH Energy Limited (ASX:BPH) investee Patagonia Genetics has acquired the rights to a recently discovered and rare high CBD hemp strain.
Known as the Carmangola Italian Hemp strain, it is an industrial hemp strain derived from Italy and cultivated for more than 15 years.
The hemp seeds are dioecious meaning that both male and female plants can be grown. The strain is mainly grown for fibre production as well as for Cannabidiol (CBD) oil extraction and resin.
The Carmagnola cultivar has a historically low Tetrahydrocannabinol (THC) reading (below 0.5%). THC is the psychoactive element of cannabis that is generally still banned for use in cannabis products in most global markets.
Whilst low in THC, the strain contains a high CBD content of 7-9%, which makes it ideal for CBD resin and oil extraction. This hemp strain is also capable of producing high quality CBD flower.
Researchers spent considerable time cultivating, testing and phenotype searching (phenotypes are the observable physical properties of an organism and include appearance, development, and behaviour) thousands of Carmagnola plants.
Forthwith, the breeder was able to identify a particular phenotype that carries exceptionally high levels of CBD compared to traditional Carmagnola, whilst maintaining THC levels well below 0.3%.
This particular phenotype of Carmagnola carries a cannabinoid profile of 18.4% CBD and 0.11% THC.
This new phenotype discovery was tested by the 'Centro Tecnológico Nacional Agroalimentario Extremadura (CTAEX), a research association inaugurated in January 2001 as a private centre for innovation and agricultural and food technology. CTAEX produced a Certificate of Analysis (COA).
This phenotype appeals to Patagonia due to its low THC.
The THC reading is substantially lower than the United States Department of Agriculture (USDA) THC limit of 0.3%, meaning it can sold worldwide as hemp, with little risk to the cultivator of exceeding THC limits.
Patagonia establishes relationship with Spanish cultivator
Patagonia recently completed due diligence on Gibraltar-based Calpernia Planters Limited, which holds various licenses which permit it to import and export hemp and cannabis related genetic material, but with a limit on THC content of 0.3% or less.
Patagonia has entered into exclusive distribution agreement with Calpernia.
Calpernia director Michael Trinidad has an agreement in place with Calpernia and is contracted to exclusively cultivate their genetics in Spain under his license and supply them. Under current capacity, the licensed Spanish farm can supply feminised seed in the vicinity of 20,000,000-30,000,000 by mid to late 2020, with the ability to scale into 2021 and beyond.
Under the terms of the distribution deal, Patagonia can immediately begin selling this newly discovered genetic phenotype under Calpernia's hemp license.
It is expected to supply the market with genetic cuttings or clones of this phenotype by Q1 2020 and feminised seeds by Q3 2020.
Patagonia has already sent the COA results to major grow shops, distributors and licensed producers worldwide and has received significant interest to supply them with genetics for 2020 cultivations.
* Newly discovered phenotypes of the Carmagnola Hemp Cultivar
Patagonia has the exclusive global rights to the newly discovered high CBD phenotype of the Carmagnola Hemp variety, through execution of deal with Calpernia.
Under the terms of the deal, Patagonia has agreed to purchase from Calpernia the following minimum volumes of seeds in order to maintain exclusivity:
- 2020. 3,000,000 seeds;
- 2021. 10,000,000 seeds; &
- 2022. 15,000,000 seeds (capped onwards).
Patagonia will update the market as and when it enters material distributions or sale agreements on this particular phenotype.
S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.
Conflict of Interest Notice
S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.
The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.